Skyrocket Phytopharma (UK) Ltd is a digital therapeutics (DTx) and diagnostics company specialising in the early detection of peripheral neuropathy.
John Simpson, founder and managing director of the company, explains:
Neuropad® is a unique non-invasive and painless 10-minute screening test to detect early signs of foot disease in people with diabetes which can lead to the development of foot ulcers and amputations. Neuropad® is already on the NHS Tariff and is being evaluated by NICE. It was also assessed by the NHS Innovation Accelerator who called it a ‘great innovation. Neuropad® is now available to patients in Brazil and later this year will be marketed in Canada. A United States launch is planned for next year.
Neurometrics-Diab™ is a digital therapeutics (DTx) smartphone app which uses the Neuropad™ as a biomarker to produce a continuous record of a person’s neuropathy to see if it is improving, is stable or is worsening with trend-lines helping to predict outcomes. Using a smartphone camera, patients can take a photo of their test result which is then automatically sent to a web server where the photo is run through a proprietary image processing algorithm resulting in a percentage score which is recorded. Over time a trend can be calculated. The DTx app is currently at the advanced prototype stage. Versions for other medical conditions are under development.
We chose to locate to Arise Harlow because it really is an excellent high-quality location. It has everything my company needs right now and there is of course a connection with Anglia Ruskin University which I hope may mean future cooperation particularly with regard to our DTx app.
We have ambitious plans for Neurometrics-Diab™ including US FDA clearance to market it there and planned launches in Brazil and Canada within the next 12 months. We are also hoping that we can cooperate with ARU on the validation of home screening with our DTx app through at least one patient study.
To find out more about Neuropad® visit their website